Searchable abstracts of presentations at key conferences in endocrinology

ea0020p579 | Neuroendocrinology, Pituitary and Behaviour | ECE2009

Empty sella and primary autoimmune hypothyroidism

Garcia-Centeno Rogelio , Suarez-Llanos Jose-Pablo , Fernandez-Fernandez Elisa , Andia-Melero Victor , Sambo Marcel , Sanchez Petra , Jara-Albarran Antonino

Objective: To assess the association between empty sella (ES) and primary autoimmune hypothyroidism, and the possibility of a common pathogenesis.Patients and methods: We retrospectively studied all patients with presumed ES diagnosed in the last 20 years, most of whom were treated and followed up by our Endocrinology Department. Subjects with a known aetiology were excluded. Incomplete records or those with a doubtful diagnosis were also excluded. A tot...

ea0037ep678 | Pituitary: basic and neuroendocrinology | ECE2015

Long-term safety, tolerability, and efficacy of extended release somatostatin analogues

Gonzalez Javier , Garcia-Centeno Rogelio , Arnoriaga Maria , Picallo Maria , Ramirez Maria Laura , Andia Victor Manuel , Olmedilla Yoko Lucia , Lopez Aurelio , Monereo Susana

Introduction: The main indications for the somatostatin analogues (SST-A) are acromegalies and/or neuroendocrine tumors. They can increase fecal fats, which could lead to the loss of fat soluble vitamins. There are few published studies showing the effects of the long-term use.Methods: Retrospective study of patients with SST-A indicated from our endocrinology department in the last 10 years. We analysed indications and different epidemiological, clinica...

ea0099p119 | Pituitary and Neuroendocrinology | ECE2024

Management of carcinoid heart disease in neuroendocrine tumor patients: a retrospective study

Jimenez Hernando Ignacio , Gonzalez Fernandez Laura , Garcia Centeno Rogelio , Perez Noguero Marta , Gomez-Gordo Hernanz Monica , Collado Gonzalez Gloria , Losada Gata Isabel , Garcia Piorno Alberto , Gonzalez Albarran Olga

Introduction: Approximately 20% of neuroendocrine tumor (NET) patients experience carcinoid syndrome (CS), primarily associated with metastatic ileal NETs. CS manifests with symptoms such as diarrhea, flushes, and cardiac complications. Carcinoid heart disease (CHD) is a negative prognostic factor in NETs. However, the considerable variability in reported diagnoses and treatment approaches in the literature creates uncertainty about optimal management in this specific populati...

ea0081ep695 | Pituitary and Neuroendocrinology | ECE2022

Epidemiological description of 20 years of experience in the management of insulinomas in a third level hospital

Maricel Rivas Montenegro Alejandra , Ramos Roberto Jose An ez , Belinchon Sergio Santos , Gonzalez Fernandez Laura , Moreno Diego Mun oz , Fernandez Fernandez Elisa , Salas Marcel Sambo , Hualpa Juan Carlos Percovich , Gonzalez Albarran Olga , Garcia Centeno Rogelio

Introduction: Insulinoma, despite its low incidence of 0.4%, it is the most common functioning pancreatic neuroendocrine tumor. Most are benign, solitary and sporadic. Around 10% can be malignant and 5-10% are part of MEN-1. On certain occasions, the differential diagnosis is difficult when there is a history of Diabetes Mellitus (DM). Our objective was to describe clinical-epidemiological data and its diagnostic-therapeutic management.Materials and Meth...

ea0090rc6.3 | Rapid Communications 6: Endocrine-related Cancer | ECE2023

Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain

Lamas Cristina , Remon Pablo , Soto-Moreno Alfonso , Fajardo-Montanana Carmen , Biagetti Betina , Guerrero Fernando , Castro Marta Araujo , Mora Mireia , Hanzu Felicia Alexandra , Iglesias Pedro , Garcia Centeno Rogelio , Camara-Gomez Rosa

Introduction: Current guidelines propose temozolomide (TMZ) as the first-line chemotherapy for aggressive pituitary neuroendocrine tumors (PitNETs), but no clinical trials have been conducted and clinical experience in this context is limited.Patients and methods: A retrospective study of patients with aggressive pitNETs treated with TMZ was conducted by the members of the Neuroendocrinology Working Area of the Spanish Society of Endocrinology and Nutrit...

ea0090ep686 | Pituitary and Neuroendocrinology | ECE2023

Inferior petrosal sinus sampling and stimulation with CRH: 18 years of experience in a tertiary hospital

Montenegro Alejandra Maricel Rivas , Anez Roberto , Gonzalez Fernandez Laura , Munoz Diego , Garcia Piorno Alberto , Losada Gata Isabel , Gomez-Gordo Hernanz Monica , Collado Gonzalez Gloria , Carlos Percovich Juan , Gonzalez Albarran Olga , Garcia Centeno Rogelio

Background: Inferior petrosal sinus sampling (IPSS) is indicated in the diagnosis of adrenocor-ticotropic hormone (ACTH)-dependent Cushing’s syndrome (CS), especially when the results of the initial diagnostic tests are discordant.Objective: To describe the patients who underwent this invasive functional test in a tertiary hospital.Methods: This was an observational study of a retrospective cohort of patients with ACTH- depend...

ea0032p868 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Prevalence of escape and lipodystrophy in patients treated with Pegvisomant. A multicenter study

Sesmilo Gemma , Resmini Eugenia , Bernabeu Ignacio , Aller Javier , Soto Alfonso , Marazuela Monica , Mora Mireia , Pico Antonio , Fajardo Carmen , Torres Elena , Alvarez-Escola Cristina , Garcia-Centeno Rogelio , Blanco Concepcion , Camara Rosa , Gaztambide Sonia , Salinas Isabel , Del Pozo Carlos , Castells Ignasi , Villabona Carles , Webb Susan

Pegvisomant (peg) is an effective treatment for acromegaly.Aim: To investigate the prevalence of escape and the incidence of lipodystrophy with peg treatment.Methods: Multicenter retrospective study. Escape was defined as loss of control in patients previously controlled under a stable dose of peg, without any other treatment change. Lipodystrophy was defined as either hypertrophy or atrophy of subcutaneous tissue in areas of drug ...

ea0099p524 | Pituitary and Neuroendocrinology | ECE2024

Differences in the efficacy of second-line therapies on the biochemical control of acromegaly in patients with GH secreting pituitary neuroendocrine tumors (Pit-NETs) and GH and PRL cosecreting Pit-NETs

Araujo Castro Marta , Vicente Almudena , Cordido Fernando , Luis Menendez Torre Edelmiro , Pascual-Corrales Eider , Venegas Moreno Eva , Garcia Centeno Rogelio , Villar Taibo Rocio , Guerrero Fernando , Abellan Galiana Pablo , A Hanzu Felicia , Fajardo-Montanana Carmen , Novo Cristina , Camara Rosa , Dolores Aviles Perez Maria , Marazuela Monica , Biagetti Betina , Puig-Domingo Manel

Aim: To evaluate the efficacy of second-line therapies in patients with acromegaly caused by a GH and PRL cosecreting pituitary neuroendocrine tumor (GH&PRL-Pit-NET) and those caused by a GH-Pit-NET.Methods: A multicenter retrospective clinical practice study of 679 patients with acromegaly in follow-up in 33 tertiary hospitals (ACRO-SPAIN study). For this analysis, only patients on treatment with pasireotide or pegvisomant in monotherapy or in combi...